Deutsche Bank sets Climb Bio price target at $28 per share
Deutsche Bank has set a $28 per share price target on Climb Bio, according to Dow Jones Newswires citing Benzinga ratings data.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Deutsche Bank has set a price target of $28 per share on Climb Bio (CLYM), Dow Jones Newswires reports.
The report also links to Benzinga's analyst ratings page for the stock. No further details are given in the original text.
why it matters
Single analyst price-target changes like this usually matter mainly to investors in the specific stock and rarely move the broader market. The bank's target can serve as one reference point for those assessing the company.
tags
instruments
sources
- Climb Bio Price Target Announced at $28.00/Share by Deutsche Bank — Dow Jones Newswires, 20 October 2026 at 18:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗